Quantcast

Industry news that matters to you.  Learn more

Archives for February 2011

CIT and Stemina Biomarker Discovery Announce European Partnership for Toxicology Testing

CIT Safety and Health Research Laboratories and Stemina Biomarker Discovery yesterday announced a strategic partnership for the distribution of Stemina’s devTOX assay in Europe. CIT will further work with Stemina to validate the test for use under the REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) initiative. Starting in 2012, REACH will require manufacturers and importers to register and test all chemicals and compositions containing chemicals.

Almac Announces Launch of Bioinformatics Consultancy

Almac’s Diagnostics business unit announced the launch of its Bioinformatics Consultancy service yesterday.

Almac’s Bioinformatics consultancy supports discovery and development of biomarkers as well as enabling an in-depth understanding of biology by partnering with customers in the pharmaceutical, biotech and diagnostics setting from the initial study design through to the interpretation of data results.

IMULAN Identifies Biomarker to Diagnose Atopic Dermatitis

IMULAN BioTherapeutics has identified a diagnostic biomarker for atopic dermatitis. Using dogs as the atopic model, researchers found a highly significant increase in the expression of the biomarker in dogs with dermatitis compared to normal dogs.

IU Personalized Medicine Institute to Develop Targeted and Individualized Treatments

Indiana University has announced a major commitment to research in one of health care’s most promising fields with the creation of the Indiana Institute for Personalized Medicine.

Cincinnati Children’s Hospital Medical Center Researchers Identify Biomarkers of Poor Outcomes in Preterm Infants

Researchers at Cincinnati Children’s Hospital Medical Center have identified biomarkers of poor outcomes in preterm infants that may help identify new approaches to prevention. The study investigated a polymorphism in a gene important for the immune system. Scientists found that the polymorphism raises the risk of bad outcomes in preterm infants, including death, necrotizing enterocolitis (death of intestinal tissue), and gram negative sepsis, an overwhelming infection.